119 related articles for article (PubMed ID: 37097644)
21. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy.
Smith JJ; Strombom P; Chow OS; Roxburgh CS; Lynn P; Eaton A; Widmar M; Ganesh K; Yaeger R; Cercek A; Weiser MR; Nash GM; Guillem JG; Temple LKF; Chalasani SB; Fuqua JL; Petkovska I; Wu AJ; Reyngold M; Vakiani E; Shia J; Segal NH; Smith JD; Crane C; Gollub MJ; Gonen M; Saltz LB; Garcia-Aguilar J; Paty PB
JAMA Oncol; 2019 Apr; 5(4):e185896. PubMed ID: 30629084
[TBL] [Abstract][Full Text] [Related]
22. Impact of residual nodal involvement after complete tumor response in patients undergoing neoadjuvant (chemo)radiotherapy for rectal cancer.
Erkan A; Mendez A; Trepanier M; Kelly J; Nassif G; Albert MR; Lee L; Monson JRT
Surgery; 2019 Oct; 166(4):648-654. PubMed ID: 31378480
[TBL] [Abstract][Full Text] [Related]
23. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
[TBL] [Abstract][Full Text] [Related]
24. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
25. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F; Gonzalez D; Cunningham D; Hulkki Wilson S; Peckitt C; Giralt J; Glimelius B; Roselló Keränen S; Wotherspoon A; Brown G; Tait D; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1430-6. PubMed ID: 24582914
[TBL] [Abstract][Full Text] [Related]
26. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.
Fernandez LM; São Julião GP; Figueiredo NL; Beets GL; van der Valk MJM; Bahadoer RR; Hilling DE; Meershoek-Klein Kranenbarg E; Roodvoets AGH; Renehan AG; van de Velde CJH; Habr-Gama A; Perez RO;
Lancet Oncol; 2021 Jan; 22(1):43-50. PubMed ID: 33316218
[TBL] [Abstract][Full Text] [Related]
27. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.
Dossa F; Chesney TR; Acuna SA; Baxter NN
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):501-513. PubMed ID: 28479372
[TBL] [Abstract][Full Text] [Related]
28. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
[TBL] [Abstract][Full Text] [Related]
29. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
[TBL] [Abstract][Full Text] [Related]
30. Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer.
Policicchio A; Mercier J; Digklia A; Voutsadakis IA
J Gastrointest Cancer; 2019 Dec; 50(4):894-900. PubMed ID: 30353366
[TBL] [Abstract][Full Text] [Related]
31. Intensified Total Neoadjuvant Therapy
DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
[TBL] [Abstract][Full Text] [Related]
32. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Sun PL; Li B; Ye QF
Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
[TBL] [Abstract][Full Text] [Related]
33. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
[TBL] [Abstract][Full Text] [Related]
34. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
Derbel O; Wang Q; Desseigne F; Rivoire M; Meeus P; Peyrat P; Stella M; Martel-Lafay I; Lemaistre AI; de La Fouchardière C
BMC Cancer; 2013 Apr; 13():200. PubMed ID: 23617638
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer.
Sada YH; Tran Cao HS; Chang GJ; Artinyan A; Musher BL; Smaglo BG; Massarweh NN
J Surg Res; 2018 Jun; 226():15-23. PubMed ID: 29661280
[TBL] [Abstract][Full Text] [Related]
36. A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management.
Weiser MR; Chou JF; Kim JK; Widmar M; Wei IH; Pappou EP; Smith JJ; Nash GM; Paty PB; Cercek A; Saltz LB; Romesser PB; Crane CH; Garcia-Aguilar J; Schrag D; Gönen M
JAMA Netw Open; 2022 Sep; 5(9):e2233859. PubMed ID: 36173634
[TBL] [Abstract][Full Text] [Related]
37. Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.
Peng YF; Yu WD; Pan HD; Wang L; Li M; Yao YF; Zhao J; Gu J
World J Gastroenterol; 2015 Feb; 21(6):1851-6. PubMed ID: 25684951
[TBL] [Abstract][Full Text] [Related]
38. The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study.
Bahnassy AA; Abdel-Azim YA; Ezzat S; Abdellateif MS; Zekri AN; Mohanad M; Salama A; Khaled H
Mol Biol Rep; 2020 Dec; 47(12):9645-9657. PubMed ID: 33174084
[TBL] [Abstract][Full Text] [Related]
39. [Risk factor analysis on anastomotic leakage after laparoscopic surgery in rectal cancer patient with neoadjuvant therapy and establishment of a nomogram prediction model].
Jiang W; Feng MY; Dong XY; Dong SM; Zheng JX; Liu XM; Liu WJ; Yan J
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Aug; 22(8):748-754. PubMed ID: 31422613
[No Abstract] [Full Text] [Related]
40. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
